ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Material-Encoded Synchronization of Immunogenic Cell Death With Adenosine A2A Receptor Blockade Reprograms the Tumor Microenvironment.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Adenosine rapidly suppresses antitumor immunity through the adenosine A2A receptor (A2AR). Immunogenic cell death (ICD) releases extracellular ATP, which can be rapidly converted into immunosuppressive adenosine. We therefore designed BSCS@PHY to synchronize ICD induction with local A2AR blockade in the same spatiotemporal window, aiming to protect antigen priming from adenosine-mediated suppression. BSCS@PHY integrates a bismuth-copper diselenide core for photothermal heating, glutathione depletion, and chemodynamic hydroxyl-radical generation; hyaluronic-acid-modified phase-change materials for on-site activation; the A2AR antagonist SCH442416 for local A2AR blockade; and yeast cell wall (YCW) components for innate adjuvanticity. Thermography-guided irradiation confines activation within a controlled window, melts the phase-change shell to expose the catalytic surface, and coordinates ICD amplification with co-localized A2AR blockade and dendritic-cell activation. In 4T1 tumors, BSCS@PHY enables image-guided activation, enhances ICD hallmarks, lowers adenosine signaling, promotes dendritic-cell maturation and T-cell priming, and improves tumor control, with additional benefit when combined with anti-PD-L1. Loss-of-function comparisons support nonredundant contributions of A2AR blockade and YCW-mediated adjuvanticity. This material-encoded strategy aligns danger-signal generation with local A2AR blockade in the same tumor niche and offers a framework for pairing ICD induction with metabolic-checkpoint control in cold tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.